QualityDipStocks / Finance · Specialty Insurers
Accelerant ARX
Outside our quality screen, so we don’t track its dips. It’s at its 52-week high.
Outside our quality screen. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- $19.68price +1%
- Off 52-wk high
- at the high
- Risk vs market
- Lowbeta 0.05
4 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for ARX: Capital spending isn't tagged in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much ARX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 5.5× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.05
- Volatility
- 71% vs 13% SPY
- Correlation SPY
- 0.01
- Correlation QQQ
- −0.07
Valuation details
MV $19.68
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
GrowthSales grew 55% to $1.1B over the last 12 months vs the 12 months before (SEC filings).
GrowthSales compounded 63% a year from FY2023 to FY2025.
Balance sheetNet cash of $1.5B: cash and short-term investments exceed debt (Jun 30, 2026).
Balance sheetDebt / equity of 0.2×, below the 0.7× median for the 46 Finance companies we cover.
Top bearish points 5 of 5
ProfitabilityLost $1.4B over the last 12 months (net income, SEC filings).
Cash returnsShare count up 6.7% in a year: existing holders are being diluted.
ValuationPrice / book of 6.0×, above the 1.7× median for the 296 Finance companies we cover.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%.
RiskReports earnings Nov 11 (consensus EPS $0.20): results can move the price sharply and reset Market Value.
All fundamentals
Sales +55%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 3.75×
- Price / book
- 5.99×
- Market cap
- $4.3Blisted
- Enterprise value
- $2.8B
Growth
- Revenue, 12 months
- $1.1B
- Sales growth, 12 months
- +54.6%vs the 12 months before
- Sales growth, 3 yrs
- +62.9%/yrfrom FY2023
- Diluted EPS, 12 months
- −$7.23
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$1.4B
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- −119.3%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- n/an/m: very small or negative equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $1.6B
- Total debt
- $120M
- Net cash
- $1.5B
- Debt / equity
- 0.17×
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +6.7%diluted shares vs a year ago
- Stock-based comp
- $89M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Accelerant’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-1.5B · Sales +57%
- Free cash flow, 12 months−$1.5B
- Free-cash-flow yield−34.4%
- Free-cash-flow margin−138%
- Gross margin65%
- Operating margin16%
- Return on equity−222%
- Sales growth (latest quarter vs year-ago quarter)+57%
- Net debt / EBITDA−14.1×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $19.81
- 52-wk lowlowest close, 1 year$9.36−52.8%
- Market Valueavg paid since Aug 14$19.68−0.7%
- PriceMon Nov 2 close$19.81you are here
- 52-wk highhighest close, 1 year$19.88+0.4%
Momentum & 52-week range
RSI 65 · 5 days −0.1%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 11
- DateWed Nov 11
- Consensus EPS$0.20
- Year-ago EPS$0.38
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
ARX is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Accelerant in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Specialty Insurers
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.